|
|
|
Volumn 12, Issue SUPPL. 3, 2014, Pages
|
|
Rapid development and scale-up through strategic partnership: Case study of an integrated approach to cell-line and process development for therapeutic antibodies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AFUCOSYLATION;
ANTIBODY;
BIOSIMILAR AGENT;
MONOCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
UNCLASSIFIED DRUG;
ANALYTIC METHOD;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ANTIBODY TITER;
ANTIGEN BINDING;
AUTOIMMUNE DISEASE;
BATCH PROCESS;
BINDING AFFINITY;
CELL CULTURE;
CELL LINE;
CHO CELL LINE;
CHO K1 CELL;
CHO M CELL LINE;
CHROMATIN;
CLONE;
COPY NUMBER VARIATION;
DNA TRANSFECTION;
DOWNSTREAM PROCESSING;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SCREENING;
ELECTROPORATION;
EPIGENETICS;
FED BATCH CULTURE;
FUCOSYLATION;
GENE SILENCING;
GENETIC TRANSCRIPTION;
HUMAN;
MAMMAL CELL;
NEOPLASM;
POLYMERASE CHAIN REACTION;
PROCESS DEVELOPMENT;
PRODUCTIVITY;
PROTEIN EXPRESSION;
QUANTITATIVE ANALYSIS;
RECOMBINANT GENE;
SCALE UP;
SHORT SURVEY;
TEMPERATURE;
|
|
EID: 84906336122
PISSN: 15426319
EISSN: None
Source Type: Trade Journal
DOI: None Document Type: Short Survey |
|
Times cited : (2)
|
|
References (3)
|
